SuperGen Reports 2007 Third Quarter Financi...(eptember 30 ...),Health

2007 2006 2007 2006

Revenues:

Net product revenue $ - $ 2,228 $ 621 $ 9,096

Development and license revenue

from MGI PHARMA, Inc - 5,064 - 25,064

Royalty revenue 6,123 1,043 14,536 1,043

Total revenues 6,123 8,335 15,157 35,203

Costs and operating expenses:

Cost of product revenue - 482 221 1,877

Research and development 6,170 4,651 17,185 11,509

Selling, general,

and administrative 3,072 6,753 10,344 19,312

Acquired in-process research

and development - - 9,968 16,318

Gain on sale of products (1,828) - (27,677) -

Total costs and

operating expenses 7,414 11,886 10,041 49,016

Income (loss) from operations (1,291) (3,551) 5,116 (13,813)

Interest income 1,044 796 3,027 1,794

Gain on disposition of investment

in AVI BioPharma stock resulting

from exercise of warrant - - - 780

Other income 12 - 33 -

Change in valuation of derivatives - 654 - 1,327

Income (loss) before income tax (235) (2,101) 8,176 (9,912)

Income tax benefit (provision) 427 (217) (236) (252)

Net income (loss) $ 192 $(2,318) $ 7,940 $(10,164)

Net income (loss) per common share:

Basic $ 0.00 $ (0.04) $ 0.14 $ (0.19)

Diluted $ 0.00 $ (0.04) $ 0.14
'/>"/>